| Taro Pharmaceuticals North America, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120065182 | STABILIZING COMPOSITIONS FOR ANTIBIOTICS AND METHODS OF USE - The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v). | 03-15-2012 |
| 20120010175 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE - The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes. | 01-12-2012 |
| 20100227918 | STREPTOMYCES-DERIVED ANTIMICROBIAL COMPOUND AND METHOD OF USING SAME AGAINST ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates to a novel antimicrobial compound of lactoquinomycin that is highly effective against many antibiotic-resistant gram-positive bacteria; namely, methicillin-resistant and vancomycin-resistance | 09-09-2010 |
| 20100130760 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE - The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5±0.2 degrees 2θ. | 05-27-2010 |
| 20100048451 | NOVEL SPILL-RESISTANT FORMULATIONS COMPRISING HYDROCOLLOIDAL POLYMERS - The invention relates to novel spill resistant formulations comprising two or more hydrocolloidal polymers and an effective amount of a pharmaceutically active agent. The formulations have a viscometric yield value of a semi-solid, and a pH and spill-resistant consistency allowing for easier preparation and use of the pharmaceutical composition. | 02-25-2010 |
| 20090247575 | STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS - The present invention relates to a pharmaceutical composition for oral administration comprising an exceptionally labile active agent, a stabilizing vehicle comprising liquid triglycerides and a desiccant, wherein the composition is storage stable for an extended period without substantial degradation of the active agent. | 10-01-2009 |
| 20090124823 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE - The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes. | 05-14-2009 |
| 20090124822 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE - The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes. | 05-14-2009 |
| 20090104125 | Stable liquid desoximethasone compositions with reduced oxidized impurity - The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C | 04-23-2009 |
| 20090048268 | ANTI-HISTAMINE COMPOSITIONS AND USE THEREOF - The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less than about 0.2%. The storage stable solution preferably contains cetirizine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid solution as well as a method of treating a mammal with a therapeutically effective amount of cetirizine in the stable pharmaceutical liquid solution. | 02-19-2009 |
